ml-1 Table 4 Cumulative MFC

ml-1. Table 4 Cumulative MFC Selleckchem LY2874455 profile of 65 clinical isolates of Candida spp. treated with 20-piperidin-2-yl-5α-pregnan-3β,20-diol (AZA) and 24(R,S),25-epiminolanosterol (EIL).     Cumulative MFC* (μg.ml-1) Species (no. isolates) Drugs 0.03 1 2 4 8 16 > 16 All species (65) AZA 1.52 3.04 12.16 16.72 34.96 44.08 100   EIL     6.08 15.20 30.40 51.68 100 Candida albicans (21) AZA     4.76 4.76 9.52 9.52 100   EIL       9.52 28.57 61.98 100 Candida parapsilosis (19) AZA   5.26 26.31 36.87 68.42 68.42 100   EIL     10.52 15.79 26.31 63.15 100 Candida tropicalis (14) AZA         35.71 64.28 100

  EIL     7.17 7.17 35.71 42.87 100 Candida glabrata (2) AZA     50 50 50 50 100   EIL       50 50 50 100 Candida krusei (1) AZA             100   EIL             100 Candida lusitaneae (1) AZA             100   EIL       100 100 100 100 Candida guilliermondii (3) AZA             100   EIL          

  100 Candida zeylanoides (1) AZA 100 100 100 100 100 100 100   EIL     100 100 100 100 100 Candida rugosa (1) AZA       100 100 100 100   EIL           Geneticin   100 * data is expressed in percentual of isolates. Ultrastructural effects The general morphology of untreated C. albicans was Quisinostat molecular weight observed using scanning (Figure 2a) and transmission (Figure 2b–c) electron microscopy. The shape of C. albicans varies from spherical (4.90 ± 0.49 μm diameter) to oval cells when viewed by scanning electron microscopy (Figure 2a). Transmission electron microscopy revealed the presence of normal cell walls with a thickness of 233 ± 25 nm (Figure 2b–c), including a thin electron-dense outer layer with delicate fibrillar structures clearly visible (f in Figure 2c). A continuous cytoplasmatic membrane (cm)lining

a homogeneous and electron-dense cytoplasm containing ribosomes, nucleus (n), and nucleoli Buspirone HCl (nu) could also be observed (Figure 2b–c). Treatment of C. albicans with MIC50 of AZA (0.25 μg.ml-1) and EIL (1.00 μg.ml-1) induced significant morphological changes, which ranged from discrete alterations to total destruction of the fungal cells. A common alteration observed after the treatment with AZA and EIL was a significant increase in cell size, from 5 μm to 7 μm in diameter (Figure 2d, g, j, and 2m). The number of altered cells was counted, and the morphological alterations appeared in 34.79% and 55.17% of the cells after treatment with AZA and EIL, respectively. Among the most frequently observed ultrastructural alterations were: (i) presence of small buds (asterisks in Figure 2d, g and 2j); (ii) irregular cell-wall surfaces (arrows in Fig. 2D and 2E); (iii) loss of cell-wall integrity, with an apparent shedding of cell components (Fig. 2G–J, white and black arrows); and (iv) a two- to three-fold increment of the cell wall thickness was observed after treatment with AZA and EIL, respectively (Figure 2f, i, l, and 2n).

Comments are closed.